Dr. Curtis Schreiber led the study at CMH’s Missouri Memory Center, which was one of only 12 clinics nationwide selected to ...

In a document (PDF) recapping a February stakeholder call that was first obtained by Stat, the agency estimates that per member per month spending on Leqembi will rise from $1.67 in 2024 to $4.67 ...

With concerns growing over the burden Leqembi could impose on healthcare infrastructure, Eisai and Biogen have trotted out data for an under-the-skin version of the Alzheimer’s disease dr ...

Leqembi got its initial accelerated approval in January with limited Medicare coverage. Now, the Centers for Medicare & Medicaid Services has opened a registry as a reimbursement pathway.

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...

Alzheimer’s drug Leqembi received full approval from the U.S. Food and Drug Administration. An expert explains why this is a milestone in the treatment of the progressive disease.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

In the U.S., Eisai projects 100,000 people will use Leqembi in three years, with more gains expected beyond that time frame, according to a press release. That could create a harsh financial ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2025 on Thursday, August 28, 2025, at 08:00 a.m. CET.

Leqembi is the second anti-amyloid drug to hit the market, but its predecessor was the controversial Aduhelm. The FDA granted accelerated approval to Aduhelm in 2021, despite a recommendation from ...

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging.